Evidence map›Paper›PMID 32973971›Full record

ArticleOncotarget2020

Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma.

Reinhard Dummer, Li Liu, Nicholas Squittieri, Ralf Gutzmer, John Lear

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 4 countries.

Reinhard DummerDepartment of Dermatology, University of Zürich, Skin Cancer Center, University Hospital, Zürich, Switzerland.
Li LiuSun Pharmaceutical Industries, Inc., Princeton, NJ, USA.
Nicholas SquittieriSun Pharmaceutical Industries, Inc., Princeton, NJ, USA.
Ralf GutzmerSkin Cancer Center Hannover, Department of Dermatology, Hannover Medical School, Hannover, Germany.
John LearManchester Academic Health Science Centre, Manchester University and Salford Royal NHS Trust, Manchester, UK.
Manchester Academic Health Science Centre · GBMedizinische Hochschule Hannover · DESun Chemical (United States) · USSun Pharma (United States) · USUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pivotal BOLT (Basal cell carcinoma Outcomes with LDE225 [sonidegib] Treatment) study established the durable efficacy and manageable toxicity of sonidegib 200 mg once daily (QD) through 42 months in patients with advanced basal cell carcinoma (BCC). This secondary analysis used expression of

Indexed as

basal cell carcinomabiomarkerGlioma-associated oncogene homolog 1Hedgehog pathway inhibitorsonidegib

Identifiers

PMID32973971
PMCPMC7500103
OpenAlexW3088910774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.